Alligator Q3 - Progress in the Clinical Programs
2022-10-21 07:35:00
Redeye discusses events and financial results in Q3 2022. Progress has been made with ATOR-1017, mitazalimab and ALG.APV-527.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking.